Stay updated on ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:57:34.000Z thumbnail image
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase 1b clinical trial evaluating the safety and efficacy of ZN-c3 in combination with other drugs for ovarian, peritoneal, or fallopian tube cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:45:52.000Z thumbnail image
  7. Check
    16 days ago
    Change Detected
    Summary
    The value on the webpage related to a Phase 1b study of ZN-c3 in combination with other drugs for ovarian, peritoneal, or fallopian tube cancer has recently changed from 27 to 28. This change likely reflects an update in the estimated primary completion date of the study, now expected to be December 31, 2024.
    Difference
    0.3%
    Check dated 2024-05-30T09:53:24.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Summary
    The value '24 Phase Study of in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian Peritoneal or Fallopian Tube Cancer 22 24' has been updated to '27 Phase Study of in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian Peritoneal or Fallopian Tube Cancer 23 27'. This change reflects an increase in the phase number and the corresponding study subjects for the clinical trial related to ovarian, peritoneal, or fallopian tube cancer.
    Difference
    3%
    Check dated 2024-05-29T08:11:38.000Z thumbnail image
  9. Check
    22 days ago
    Change Detected
    Summary
    The value Platinum-Resistant 2023-09-21 Detailed Description has been updated to Phase 1b open-label, multicenter study evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics, and pharmacodynamics of ZN-c3 in combination with other drugs for participants with platinum-resistant ovarian, peritoneal, or fallopian tube cancer.
    Difference
    32%
    Check dated 2024-05-25T05:02:19.000Z thumbnail image
  10. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as informed consent, age, health conditions, and prior treatments. Previously, no information was provided in this section.
    Difference
    35%
    Check dated 2024-05-22T21:38:33.000Z thumbnail image

Stay in the know with updates to ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ZN-c3 in Platinum-Resistant Ovarian Cancer Clinical Trial page.